Faculté de Médecine, Université Joseph Fourier, Grenoble, France.
Hum Vaccin Immunother. 2012 Oct;8(10):1454-8. doi: 10.4161/hv.21429. Epub 2012 Aug 16.
Active immunotherapy based on live attenuated bacterial vectors has matured in terms of industrial development and develops through a combination of three phenomena. First, active immunotherapy that stimulates an antigen-specific cytotoxic T-cell immune response has become a reality after several years of work. Second, there is still a need to identify vectors that can deliver antigens to the cytosol of antigen-presenting cells in vivo. Third, the recent progress in the understanding of bacterial lifestyle and in developing genetic engineering tools has enabled the design of bioengineered bugs that are capable of delivering antigens. Here, we review the mechanisms by which clinical bacterial vectors deliver antigens into the cytosol of antigen-presenting cells and summarize the development strategy of the three identified firms in this field.
基于减毒活细菌载体的主动免疫疗法在工业开发方面已经成熟，并通过三种现象的结合发展。首先，经过多年的工作，刺激抗原特异性细胞毒性 T 细胞免疫反应的主动免疫疗法已经成为现实。其次，仍然需要确定能够将抗原递送到体内抗原呈递细胞胞质溶胶中的载体。第三，对细菌生活方式的理解和开发遗传工程工具方面的最新进展使得设计能够递呈抗原的生物工程细菌成为可能。在这里，我们回顾了临床细菌载体将抗原递送到抗原呈递细胞胞质溶胶的机制，并总结了该领域三家公司的发展策略。
